acquisition – media

Good Samaritan a Senior Healthcare Provider Acquired by Sanford Health

Sanford Health, a healthcare delivery system acquired the Evangelical Lutheran Good Samaritan Society, a senior healthcare services provider for an undisclosed amount. Both South Dakota based healthcare providers announced the merge to form a $6 billion company with 47,000 employees nationwide.
- Source: Health Leaders Media
- 663
- June 29, 2018
acquisition Company Insight healthcare
Autolus Raises Impressive $150 Million for T-cell Therapy

The IPO has provided the biotech major with the financial bandwidth to aggressively pursue its new generation of CAR-T variants on a broader level, with the advancement of several therapies or the start of clinical trials over the next couple of months.
- Source: FierceBiotech
- 599
- June 25, 2018
acquisition cancer CAR-T therapies Company Insight
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

T-Stealth™ Oncolytic Virus Platform Expected to Further Strengthen Immunotherapy Platform and Capabilities
- Source: janssen
- 588
- May 3, 2018
acquisition Janssen oncolytic immunotherapies
Fresenius dumps its $4.3B Akorn buyout, and a ‘legal battle royale’ could come next

Akorn has filed a complaint in Delaware Chancery Court asking Fresenius to follow through on the pair's buyout agreement. A year after inking its $4.3 billion Akorn buyout agreement, Fresenius intends to scrap the deal. Akorn, though, isn’t having it, and analysts say a “legal battle royale” could be on the horizon.
- Source: fiercepharma
- 636
- April 26, 2018
acquisition Series
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.
- Source: Businesswire;
- 606
- April 9, 2018
acquisition CDI Market Views non-antibiotic
Astellas Takes Out Massachusetts’ Biotech Mitobridge in $390M Deal

Tokyo-based Astellas Pharma is buying Cambridge, Mass.-based Mitobridge for a total of $390 million. Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013. Under that deal, the two companies collaborated on discovering and developing drugs that target mitochondrial function. The most advanced program from the collaboration is MA-0211, which is presently in Phase I clinical trials for Duchenne muscular dystrophy (DMD). Astellas is an equity investor in Mitobridge already, and is paying $165.5 million in cash in addition to the $60 million in equity it already owns. There is also an additional $225 million in potential milestone payments. John Carroll, with Endpoints News, writes, “For years now, Salk’s Ron Evans—a celebrated serial entrepreneur in scientific circles—has been concentrating on the potential of a new pathway for turning your average couch potato rodent into Mighty Mouse—without exercise…. A couple of ...
- Source: biospace
- 709
- December 5, 2017
acquisition Astellas Clinical Trials Duchenne muscular dystrophy Market Views Series
Centinel Spine acquires Prodisc assets from J&J’s DePuy Synthes

Centinel Spine has agreed to acquire Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount, according to an OrthoWorld report.
- Source: Massdevice
- 677
- September 20, 2017
acquisition Market Views Prodisc
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 550
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
LabCorp completes $1.2B Chiltern buy

Diagnostics company LabCorp (NYSE:LH) said today that it has closed its $1.2 billion acquisition of contract research organization Chiltern International.
- Source: drugdeliverybusiness
- 674
- September 4, 2017
acquisition Clinical Market Views oncology
Resonetics Acquires Aduro Laser, Adds Disruptive Manufacturing Capability for Laser Cut Tubing

Resonetics announced today its acquisition of Aduro Laser, an emerging leader in laser processing of tubular components for the medical device industry.
- Source: prnewswire
- 524
- August 29, 2017
acquisition Company Insight laser Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.